Psychedelic Stocks Archives - Page 13 of 61

ThursdayJan 18, 2024 2:34 pm

Addiction to Gambling Could Be Treated Using Psychedelics

Addiction refers to a condition in which an individual is not able to stop engaging in a behavior or using a substance. Gambling addiction is a behavioral addiction that stimulates the reward system of the brain, much as alcohol and drugs do. This addiction is often treated using behavioral therapy, particularly cognitive behavioral therapy, which replaces unhealthy and irrational beliefs with positive, healthy ones. Now, researchers at the Center for Psychedelic Research are using brain imaging to understand behavioral addictions such as gambling and discover new approaches to treat these addictions. They are particularly focused on psychedelic treatments, given the…

WednesdayJan 17, 2024 3:35 pm

Top 2023 Studies on Ketamine’s Efficacy Against Depression, Mental-Health Illnesses

In the last couple of years, ketamine has been used to treat depression, with ketamine clinics across Canada and the United States administering the drug for the management of anxiety, depression and post-traumatic stress disorder. Ketamine is a dissociative drug commonly used as an anesthetic that causes an individual to lose consciousness and relieve pain. In high doses, ketamine can create neuroplasticity and induce psychedelic experiences. Below, we look at some studies conducted in 2023 that have explored ketamine’s effectiveness in treating a range of mental-health conditions. Ketamine for the prevention of psychiatric disorders induced by stress A study carried…

FridayJan 12, 2024 12:53 pm

Little-Known Advisory Panel Slowing Psychedelic Research in California

Currently, the state of California has the largest number of clinical studies in the country, making up more than 25% of registered clinical trials within the United States. Despite this, numerous studies that involve substances under Schedule I and II haven’t begun, even after obtaining clearance from the U.S. Drug Enforcement Administration (DEA), the U.S. Food and Drug Administration and institutional review boards. This is mainly because of the Research Advisory Panel of California (RAP-C), established under state law as the California Research Advisory Panel back in 1965. The RAP-C encourages and coordinates further studies of psychedelics and marijuana. The…

ThursdayJan 11, 2024 3:10 pm

VA to Fund Studies on Psychedelics for PTSD, Depression in Veterans

Last week, the United States Department of Veterans Affairs (VA) issued a request for applications to carry out in-depth studies on the use of psychedelic substances in the treatment of depression and post-traumatic stress disorder (PTSD). The VA revealed that it was the first time since the 1960s that the agency would be funding psychedelic research, adding that it intends to collect definitive scientific evidence of the potential safety and effectiveness of psychedelic compounds such as psilocybin and MDMA. When administered together with psychotherapy, these compounds may help treat veterans with depression and PTSD. The department also highlighted in its…

TuesdayJan 09, 2024 3:12 pm

New Study Suggests Ibogaine Banishes PTSD

A small clinical trial involving military veterans suggests that a psychedelic called ibogaine has the potential to treat traumatic brain injury (TBI) symptoms such as depression and post-traumatic stress disorder (PTSD). The Stanford University study found that the lesser-known psychedelic reduced depression and PTSD symptoms by more than 80% in veterans with TBIs. While the past few years have seen a surge of psychedelic-related studies and clinical trials, most of them have focused on classic psychedelics such as psilocybin (magic mushrooms), MDMA and LSD. These studies found that these popular psychedelics can be effective at treating the symptoms of various…

ThursdayJan 04, 2024 3:10 pm

2023 Saw Major Steps Forward for Psychedelic Reform at Both Federal, State Level

Last year was a significant year for psychedelic reform. While researchers worked hard to expand their understanding of psychedelics, several lawmakers strove to advance psychedelic reform policy at the local, state and federal levels. The result was historic psychedelic policy-related advancements throughout the year that further enabled psychedelic research and opened the door to the potential development of alternative mental health treatments. This includes the first-ever federal legislation mandating psychedelic drug-clinical trials, a novel congressional hearing, guidance from the U.S. Food and Drug Administration (FDA) on researching entheogenic substances, the launch of psilocybin services in Oregon and the chance to…

WednesdayJan 03, 2024 11:47 am

How Psychedelics Are Shaping Modern Technology

After decades of prohibition hindered any meaningful research into their potential risks and benefits, psychedelics are now attracting considerable interest from the scientific community. Multiple studies have found that classic psychedelics such as LSD, MDMA and psilocybin (magic mushrooms) can alleviate the symptoms of several hard-to-treat mental disorders. Combining psychedelic treatment with talk therapy makes the novel treatment much more effective and allows patients to gain long-term relief from minimal psychedelic doses with barely any side effects. Although current research efforts are expanding the scientific community's knowledge of psychedelics significantly, researchers first began studying hallucinogenic drugs several decades ago. In…

TuesdayJan 02, 2024 1:54 pm

USask Scientists Explore Hidden History of Psychedelics

Researchers from the University of Saskatchewan (USask) are exploring the hidden history of psychedelic drugs and working to expand the world’s clinical and cultural understanding of hallucinogens. Most of the public is unaware of the rich history of psychedelics, let alone their potential medical benefits, and Dr. Erica Dyck from USask is looking to fill this critical knowledge gap by cataloging essays and research into a book. A recent resurgence in psychedelic-related research has found that numerous classic psychedelics can treat debilitating mental disorders with few side effects. Studies have found that psychedelic-based treatments can offer long-term relief against mental…

FridayDec 29, 2023 1:00 pm

Research Suggests Psilocybin Group Therapy Holds Promise for Treating Depressed Cancer Patients

A study published in the American Cancer Society’s peer-reviewed “CANCER” journal has revealed that psilocybin-assisted group therapy may help treat depression in cancer patients. Psilocybin is one of several classic psychedelics that have been subject to extensive research in recent years due to claims of medical efficacy. Study author and Sunstone Therapies cofounder and chief executive officer Manish Agrawal conducted the study to find suitable ways of addressing the immense emotional and mental distress that often accompanies a cancer diagnosis. Past research has found that hallucinogens such as psilocybin, LSD and MDMA, may be effective at offering long-term relief against…

ThursdayDec 28, 2023 12:51 pm

Biden Enacts Defense Bill Mandating Studies on Psychedelics for Military Personnel

Last week, President Joe Biden signed a defense bill containing provisions to finance trials into the therapeutic potential for psychedelics for military services members in active duty. This came a week after Congress gave its final approval and forwarded the bill to the president’s desk. The bill requires the defense department to create a process by which military service members with traumatic brain injuries or post-traumatic stress disorder could take part in clinical trials involving MDMA, psilocybin, 5-MeO-DMT and ibogaine. This list also includes eligible plant-based alternative treatments. The U.S. Department of Defense has been given 180 days within which…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Psychedelic Stocks